BCOR and TP53-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study

被引：0
|
作者：
Cerrillo, Diego Montoya [1 ]
Beshah, Fireneh [2 ]
Torres, Jaylou Velez [3 ]
Montgomery, Elizabeth [3 ]
Rosenberg, Andrew [2 ]
机构：
[1] Univ Miami Hosp, Jackson Mem Hosp, Miami, FL USA
[2] Univ Miami Hlth Syst, Miami, FL USA
[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
61
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [41] How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Loschi, Michael
    Fenaux, Pierre
    Cluzeau, Thomas
    CANCERS, 2022, 14 (18)
  • [42] What have we learned about TP53-mutated acute myeloid leukemia?
    Moazzam Shahzad
    Muhammad Kashif Amin
    Naval G. Daver
    Mithun Vinod Shah
    Devendra Hiwase
    Daniel A. Arber
    Mohamed A. Kharfan-Dabaja
    Talha Badar
    Blood Cancer Journal, 14 (1)
  • [43] Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
    Stafylidis, Christos
    Vlachopoulou, Dimitra
    Kontandreopoulou, Christina-Nefeli
    Diamantopoulos, Panagiotis T.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (04)
  • [44] Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia
    Huang, Ting
    Xu, Lanping
    Zhang, Xiaohui
    Chang, Yingjun
    Mo, Xiaodong
    Sun, Yuqian
    Huang, Xiaojun
    Wang, Yu
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (04) : 494 - 505
  • [45] CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
    Chen, Yuyan
    Zhu, Zhengyi
    Wu, Xingyu
    Li, Hui
    Guan, Wenxian
    Ren, Haozhen
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [46] FOLFOX resistance in TP53-mutated Metastatic Colorectal Cancer: mechanism and selective targeting
    Hollande, Frederic
    Behrenbruch, Corina
    Foroutan, Momeneh
    Simpson, Kaylene
    Heriot, Alexander
    CANCER SCIENCE, 2023, 114 : 739 - 739
  • [47] CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
    Yuyan Chen
    Zhengyi Zhu
    Xingyu Wu
    Hui Li
    Wenxian Guan
    Haozhen Ren
    Cell Death Discovery, 10
  • [48] Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study
    Byrne, Michael T.
    Kurian, Tony J.
    Patel, Dilan A.
    Tamari, Roni
    Hong, Sanghee
    Abdelhakim, Haitham
    Klein, Victoria
    Rojas, Patricio
    Madhavan, Raksha
    Kent, Andrew
    Logan, Aaron C.
    Lee, Catherine J.
    Husnain, Muhammad
    Manning, Benjamin M.
    Tschernia, Nicholas P.
    Dias, Ajoy L.
    Margalski, Daniel
    Goldenson, Benjamin
    Byrne, Nathalie
    Chen, Heidi
    Petrova-Drus, Kseniya
    Sengsayadeth, Salyka M.
    Goodman, Aaron M.
    Howard, Dianna S.
    Wood, William A.
    Gill, Saar
    Jimenez, Antonio M.
    Gutman, Jonathan A.
    Gowda, Lohith
    Metheny, Leland, III
    Bhatnagar, Bhavana
    Hamilton, Betty K.
    Mishra, Asmita
    Savona, Michael R.
    BLOOD, 2021, 138
  • [49] Outcomes of Patients with TP53-Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)
    Pasca, Sergiu
    Haldar, Saurav D.
    Ambinder, Alexander J.
    Webster, Jonathan
    Jain, Tania
    Dalton, William Brian
    Prince, Gabrielle T.
    Ghiaur, Gabriel
    DeZern, Amy E.
    Gojo, Ivana
    Webster, Jonathan Allen
    Schulz, Cory
    Stokvis, Kristin
    Levis, Mark J.
    Jones, Richard J.
    Gondek, Lukasz P.
    BLOOD, 2022, 140 : 10629 - 10631
  • [50] The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53-Mutated AML
    Semba, Yuichiro
    Yamauchi, Takuji
    Nakao, Fumihiko
    Nogami, Jumpei
    Ogawa, Seishi
    Akashi, Koichi
    Maeda, Takahiro
    BLOOD, 2022, 140
12345